Showing 5241-5250 of 8928 results for "".
- Estée Lauder Companies and Atropos Therapeutics Partner to Discover Botanical Senomodulatorshttps://practicaldermatology.com/news/estee-lauder-companies-and-atropos-therapeutics-partner-to-discover-senomodulators/2460500/The Estée Lauder Companies and Atropos Therapeutics are joining forces to discover botanical senomodulators or senescence-modulating chemicals. Atropos Therapeutics Inc. has a proprietary platform to identify and develop senescence-modu
- Merz Aesthetics Rolls Out “Confidence to Be” Branding Platform and Other Changeshttps://practicaldermatology.com/news/merz-aesthetics-rolls-outconfidence-to-be-branding-platform-and-other-changes/2460497/Merz Aesthetics is launching its new “confidence to be” branding platform following the conclusion of the company’s reorganization. Merz is now three independently operating businesses: medical aesthetics, therapeutics and consumer care. “The new brand
- Galderma Gives Back: Company Donates 1,200 Backpacks Filled with School Supplies to Northwest ISD Studentshttps://practicaldermatology.com/news/galderma-gives-back-company-donates-1200-backpacks-filled-with-school-supplies-to-northwest-isd-students/2460495/For the fifth consecutive year, Galderma donated backpacks filled with school supplies to Northwest Independent School District (NISD) students. This year, Galderma donated 1,200 backpacks for students in grades Kindergarten through 12, for a total of 6,105 backpacks donated since 2016.
- New Data Supports the Safety and Efficacy of Dupixent in Adults and Children with ADhttps://practicaldermatology.com/news/new-data-supports-the-safety-and-efficacy-of-dupixent-in-adults-and-children-with-ad/2460492/Two new studies reinforce the efficacy and safety of Dupixent for the treatment of atopic dermatitis in children and adults. In the Phase 3 LIBERTY AD pediatric trial data, nearly three times as many children achieved clear or almost clear skin when treated with Du
- New Dermatology Atlas to Highlight and Compare Features of Common Dermatologic Conditions in Different Skin Typeshttps://practicaldermatology.com/news/new-dermatology-atlas-to-highlight-and-compare-features-of-common-dermatologic-conditions-in-different-skin-types/2460491/Leaders from academic dermatology and education are joining together to create a comprehensive dermatology atlas to address what they say has become a well-documented gap in dermatology education. The atlas will display side-by-side images of the most common dermatology conditions in the full spe
- Third Pivotal Phase 3 Study Shows Rinvoq Plus Topical Corticosteroids Improves Skin and Itch Symptoms in Atopic Dermatitishttps://practicaldermatology.com/news/third-pivotal-phase-3-study-shows-rinvoq-plus-topical-corticosteroids-improves-skin-and-itch-symptoms-in-atopic-dermatitis/2460489/AbbVie's upadacitinib (15 mg and 30 mg, once daily) (Rinvoq) plus topical corticosteroids (TCS) met the co-primary endpoints and all secondary endpoints in AD Up, the third pivotal Phase 3 study of Rinvoq in atopic dermatitis. AD Up evaluated the efficacy and safety of both doses of upadaciti
- Meet Amber Edwards, Alastin Skincare’s New Chief Commercial Officerhttps://practicaldermatology.com/news/meet-amber-edwards-alastin-skincares-new-chief-commercial-officer/2460485/Amber Edwards is Alastin Skincare’s new Chief Commercial Officer, effective July 31, 2020 Ms. Edwards most recently served as President of North America for Sinclair Pharma. Prior to Sinclair, she was at Allergan, Inc. where she was the Vice President of International Strategic Ma
- Industry Responds to COVID-19: Cyrex Labs Offers Multiple Autoimmune Reactivity Screenhttps://practicaldermatology.com/news/industry-responds-to-covid-19-pyrex-labs-offers-multiple-autoimmune-reactivity-screen/2460484/With the risks associated with COVID-19 and because those with one autoimmune disease have a 25 percent chance of developing another, specialists say it is critical for those with autoimmune disease to use safety measures, good eating habits, and self-care to avoid contracting this or any virus.&
- Genentech’s Tecentriq plus Cotellic and Zelboraf Approved for Advanced Melanomahttps://practicaldermatology.com/news/genentechs-tecentriq-plus-cotellic-and-zelboraf-approved-for-advanced-melanoma/2460483/Tecentriq (atezolizumab) is now approved in combination with Cotellic (cobimetinib) and Zelboraf(vemurafenib) for the treatment of BRAF V600 mutation-positive advanced melanoma patients. The safety profile observed in the Tecentriq combination was consistent with the known safety profil
- Stelara Approved for PsO in Kids Ages 6-11https://practicaldermatology.com/news/stelara-approved-for-pso-in-kids-ages-6-11/2460482/Stelara® (ustekinumab) is now approved for pediatric patients (6-11 years of age) with moderate to severe plaque psoriasis (PsO). Stelara, from The Janssen Pharmaceutical Companies of Johnson & Johnson, targets both interleukin (IL)-12 and IL-23